| Primary |
| Product Used For Unknown Indication |
31.9% |
| Herpes Zoster |
27.5% |
| Stem Cell Transplant |
7.7% |
| Chronic Lymphocytic Leukaemia |
3.3% |
| Herpes Virus Infection |
3.3% |
| Bronchopulmonary Aspergillosis |
2.2% |
| Encephalitis Herpes |
2.2% |
| Herpes Simplex |
2.2% |
| Hypertension |
2.2% |
| Immunosuppressant Drug Therapy |
2.2% |
| Infection |
2.2% |
| Overdose |
2.2% |
| Prophylaxis |
2.2% |
| Stomatitis |
2.2% |
| Contraception |
1.1% |
| Cytomegalovirus Gastroenteritis |
1.1% |
| Epilepsy |
1.1% |
| Genital Herpes |
1.1% |
| Glioblastoma |
1.1% |
| Herpes Zoster Ophthalmic |
1.1% |
|
| Drug Ineffective |
8.6% |
| Stevens-johnson Syndrome |
8.6% |
| Toxic Epidermal Necrolysis |
8.6% |
| Depressed Level Of Consciousness |
5.7% |
| Herpes Zoster |
5.7% |
| Incorrect Dose Administered |
5.7% |
| Myelitis Transverse |
5.7% |
| Neurotoxicity |
5.7% |
| Overdose |
5.7% |
| Product Substitution Issue |
5.7% |
| Pyrexia |
5.7% |
| Toxicity To Various Agents |
5.7% |
| Abdominal Distension |
2.9% |
| Acute Graft Versus Host Disease In Skin |
2.9% |
| Agranulocytosis |
2.9% |
| Alopecia Areata |
2.9% |
| Altered State Of Consciousness |
2.9% |
| Biliary Cirrhosis Primary |
2.9% |
| Blood Creatinine Increased |
2.9% |
| Confusional State |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
53.6% |
| Prophylaxis |
5.6% |
| Cardiac Failure |
4.7% |
| Lung Disorder |
4.7% |
| Herpes Zoster |
4.3% |
| Hiv Infection |
3.3% |
| Chronic Lymphocytic Leukaemia |
3.1% |
| Febrile Bone Marrow Aplasia |
2.9% |
| Acute Myeloid Leukaemia |
2.3% |
| Haematological Malignancy |
2.3% |
| Stem Cell Transplant |
1.7% |
| Graft Versus Host Disease |
1.6% |
| Drug Use For Unknown Indication |
1.4% |
| Hodgkin's Disease |
1.4% |
| Stomatitis |
1.4% |
| Antiviral Prophylaxis |
1.2% |
| Diffuse Large B-cell Lymphoma |
1.2% |
| Herpes Virus Infection |
1.2% |
| Hodgkin's Disease Stage Iv |
1.2% |
| Myelodysplastic Syndrome |
1.2% |
|
| Eosinophilia |
7.5% |
| Hypertriglyceridaemia |
7.5% |
| Renal Failure |
7.5% |
| Agranulocytosis |
5.7% |
| Cataract |
5.7% |
| Completed Suicide |
5.7% |
| Gastrointestinal Haemorrhage |
5.7% |
| Hepatitis Cholestatic |
5.7% |
| Pyrexia |
5.7% |
| Rectal Haemorrhage |
5.7% |
| Renal Failure Acute |
5.7% |
| Generalised Erythema |
3.8% |
| Hallucination, Visual |
3.8% |
| Mixed Liver Injury |
3.8% |
| Pleural Effusion |
3.8% |
| Renal Impairment |
3.8% |
| Toxicity To Various Agents |
3.8% |
| Vomiting |
3.8% |
| Weight Increased |
3.8% |
| Abdominal Pain |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.7% |
| Prophylaxis |
13.7% |
| Diffuse Large B-cell Lymphoma |
12.2% |
| Multiple Myeloma |
3.8% |
| T-cell Lymphoma |
3.5% |
| Chronic Lymphocytic Leukaemia |
3.3% |
| Infection Prophylaxis |
2.9% |
| Acute Myeloid Leukaemia |
2.8% |
| Plasma Cell Myeloma |
2.6% |
| Pain |
2.4% |
| Hypertension |
2.3% |
| Drug Use For Unknown Indication |
2.2% |
| Hiv Infection |
2.2% |
| Antiviral Prophylaxis |
2.1% |
| Mantle Cell Lymphoma |
2.0% |
| Premedication |
1.9% |
| B-cell Lymphoma |
1.8% |
| Antifungal Prophylaxis |
1.7% |
| Constipation |
1.5% |
| Acute Lymphocytic Leukaemia |
1.4% |
|
| Sepsis |
11.6% |
| Pulmonary Embolism |
8.7% |
| Pyrexia |
7.2% |
| Renal Failure Acute |
6.9% |
| Febrile Neutropenia |
6.5% |
| Pneumonia |
6.5% |
| Constipation |
5.8% |
| Septic Shock |
5.1% |
| Renal Failure |
4.3% |
| Cardiomyopathy |
4.0% |
| Vertigo |
4.0% |
| Death |
3.6% |
| Infection |
3.6% |
| Nausea |
3.6% |
| Thrombocytopenia |
3.6% |
| Cytomegalovirus Infection |
3.2% |
| Deep Vein Thrombosis |
3.2% |
| Cytolytic Hepatitis |
2.9% |
| Malaise |
2.9% |
| Pancytopenia |
2.9% |
|
| Interacting |
| Hiv Infection |
41.7% |
| Blood Cholesterol Increased |
16.7% |
| Erysipelas |
16.7% |
| Herpes Simplex |
8.3% |
| Herpes Zoster |
8.3% |
| Hyperpyrexia |
8.3% |
|
| Rash Papular |
50.0% |
| Red Blood Cell Count Abnormal |
50.0% |
|
